Novel Oral LNAD+ Increases Intracellular NAD and Metabolic Flux Without Elevating Circulating NAD: Evidence from a Randomized Controlled Trial

In a randomized controlled trial, a novel oral formulation of LathMized NAD+ (LNAD+) significantly increased intracellular NAD levels and metabolic flux in healthy adults without elevating circulating NAD, demonstrating effective compartment-selective delivery and a favorable safety profile.

The Gist

The Big Picture: The "Battery" Problem

Imagine your body's cells are like tiny cities. Inside every building in these cities, there are power plants (mitochondria) that keep the lights on and the machines running. The fuel for these power plants is a molecule called NAD+.

As we get older, our "fuel tanks" start to run low. This leads to the lights flickering, the machines slowing down, and the city feeling tired. This is why we feel the effects of aging. Scientists have been trying to figure out how to refill these tanks.

The Old Way vs. The New Way

For a while, the main strategy was to send in precursors (like Nicotinamide Riboside or NMN). Think of these precursors as delivery trucks carrying raw materials (bricks and mortar) to the construction site. The cells then have to build the fuel themselves.

• The Problem: The gut is like a busy customs checkpoint. Many of these trucks get stopped, inspected, or broken down before they even reach the city. By the time the materials arrive, a lot of them are lost or turned into something else. Also, the city's construction crews (enzymes) can get overwhelmed, creating a bottleneck.

The New Solution (LNAD+):
Instead of sending raw materials, this study tested a new product called LathMized™ NAD+ (LNAD+).

• The Analogy: Imagine instead of sending bricks, you send a fully assembled, pre-packaged energy battery directly to the power plant.
• The Innovation: NAD+ is usually a fragile molecule that breaks down instantly in your stomach (like a soap bubble popping in acid). The researchers used a special "LathMized" process to stabilize this battery, wrapping it in a way that protects it from the stomach acid and helps it slip through the gut wall without getting broken down.

What Did the Study Find?

The researchers gave this new "pre-packaged battery" to 50 healthy adults (aged 45–75) for 5 days. They took blood samples to see what happened in two different places:

1. The "Street" (Circulating NAD): The liquid part of the blood (plasma).
2. The "Buildings" (Intracellular NAD): Inside the actual blood cells.

The Results were surprising and exciting:

• The "Buildings" got full: The amount of fuel inside the cells jumped by 53%. It was like turning a flickering light bulb into a bright spotlight.
• The "Street" stayed empty: The amount of fuel floating around in the liquid blood did not change.

Why is this a good thing?
Think of it like a VIP delivery. If you order a pizza and it sits on the doorstep (circulating blood) for hours, it gets cold and soggy. But if the delivery guy walks straight into your house and puts it on your table (inside the cell), it's hot and ready to eat.
The study proved that this new method delivers the fuel directly where it's needed, bypassing the "street" entirely. It didn't just float around; it got inside the cells.

Did It Actually Work? (The Smoke Test)

To prove the fuel was actually being used and not just sitting there, the researchers looked for "exhaust fumes."

• When your body burns fuel, it creates waste products (catabolites).
• The study found a massive spike in these waste products (specifically MeNAM and 2PY).
• The Metaphor: It's like seeing a factory suddenly start producing a lot of smoke. You know the factory is running! This proved the body was actively processing and using the new NAD+.

Was It Safe?

Yes. The study was like a "stress test" for the new fuel.

• Side Effects: Almost none. Only one person felt a little nauseous (like a mild stomach ache), and it went away quickly.
• Vitals: Heart rate, blood pressure, and liver/kidney function remained normal.
• Immune System: There was a tiny, temporary bump in white blood cells, but no signs of infection or inflammation. It looked more like the immune cells were just "waking up" and getting ready to work, rather than fighting a disease.

The Takeaway

This study is a Phase 0/1b trial, which is basically the first major "proof of concept" in humans.

In simple terms:
Scientists found a way to package NAD+ so it survives the trip through your stomach and gets straight into your cells, bypassing the usual traffic jams and bottlenecks. It worked fast (in just 5 days), it worked big (a 53% increase), and it was safe.

What's next?
This is just the first step. Now scientists need to see if taking this for months or years keeps the "lights on" in our aging bodies and if it actually helps us live longer, healthier lives. But for now, we know that this new "pre-packaged battery" can successfully reach the power plants.

Technical Summary

1. Problem Statement

Nicotinamide adenine dinucleotide (NAD+) is a critical coenzyme for cellular metabolism, DNA repair, and epigenetic regulation. Its levels decline significantly with age, contributing to mitochondrial dysfunction, genomic instability, and immunosenescence. While NAD+ precursors (e.g., NR, NMN) are used to restore levels, they face significant bioavailability barriers:

• Metabolic Bottlenecks: Gut microbiome enzymes deamidate precursors before absorption, and hepatic first-pass metabolism (via NNMT) rapidly clears them.
• Tissue Disconnect: Systemic (blood) NAD+ increases often do not translate to intracellular increases in metabolically active tissues.
• Direct NAD+ Limitations: Direct oral administration of NAD+ has historically been deemed unviable due to poor stability, high molecular weight, extreme hydrophilicity (logP = −11.6), and rapid enzymatic degradation in the GI tract (half-life <5 mins), resulting in estimated bioavailability <2%.

The Gap: There is a lack of clinical evidence demonstrating that oral NAD+ can bypass these barriers to effectively increase intracellular NAD (icNAD) without merely elevating circulating plasma levels, nor is there a clear understanding of its metabolic flux in humans.

2. Methodology

Study Design:

• Type: Double-blind, randomized, placebo-controlled Phase 0/1b trial (RENEWAL-NAD+; NCT07336836).
• Population: 60 healthy adults aged 45–75 years (Primary analysis cohort: $N=50$; 23 LNAD+, 27 Placebo).
• Intervention: 5 days of oral LathMized™ NAD+ (LNAD+), a proprietary formulation using a "green chemistry" physical pharmacy process to modulate supramolecular organization without altering chemical identity.
  • Dosing: 2000 mg/day (four 500 mg doses, QID) for 5 days.
  • Formulation: LNAD+ contained 50% NAD+ and 50% Polyethylene Glycol (PEG) filler; Placebo was 100% PEG.
  • Administration: "Swish-and-swallow" protocol to potentially leverage buccal/sublingual absorption.

Endpoints & Measurements:

• Primary Endpoints:
  • Intracellular NAD (icNAD): Measured in whole blood (predominantly erythrocytes).
  • Circulating NAD (cirNAD): Measured in separated plasma.
  • Timing: Baseline (two draws), Day 4 (after ~14 doses), Day 6 (24h after final dose).
• Secondary Endpoints:
  • Metabolic Flux: Plasma levels of NAD+ catabolites (MeNAM, 2PY, NAM, Quinolinate, Trigonelline).
  • Safety: Clinical labs (CBC, liver/kidney function), vitals, patient-reported outcomes (RoS, DASS-21), and wearable data (Fitbit).
• Statistical Analysis:
  • Mixed Models for Repeated Measures (MMRM) with Kenward-Roger approximation.
  • Nonparametric bias-corrected and accelerated (BCa) bootstrap confidence intervals.
  • Multiplicity correction via Benjamini-Hochberg (FDR) and Šidák methods.

3. Key Contributions

• Proof of Concept for Oral NAD+: Demonstrates that a physiochemically modified oral NAD+ formulation can achieve rapid, substantial intracellular accumulation, challenging the dogma that oral NAD+ is ineffective.
• Compartmental Specificity: Establishes a dissociation between circulating and intracellular pools, showing that the intervention targets the intracellular compartment specifically without causing systemic plasma accumulation.
• Metabolic Flux Evidence: Provides pharmacodynamic evidence that the administered NAD+ is not just accumulating but is actively entering metabolic catabolic pathways (evidenced by catabolite spikes).
• Methodological Rigor: Utilizes a dual-compartment measurement strategy (icNAD vs. cirNAD) to resolve the ambiguity common in previous whole-blood NAD+ studies.

4. Key Results

Primary Endpoints (NAD+ Levels):

• Intracellular NAD (icNAD): The LNAD+ group showed a massive, statistically significant increase compared to placebo.
  • Day 6: +53% increase vs. placebo ($p = 5.48 \times 10^{-14}$; Hedges' $g = 3.66$).
  • Magnitude: Mean icNAD rose from ~28.8 μM to 43.5 μM in the treatment group, while the placebo group remained stable.
  • Responder Rate: 78.3% of LNAD+ participants achieved >30% increase.
• Circulating NAD (cirNAD): No significant change was observed in plasma NAD+ levels ($p = 0.60$), confirming the intervention did not simply flood the extracellular space.

Secondary Endpoints (Metabolism & Safety):

• Metabolic Flux: Significant increases in downstream catabolites were observed, confirming active metabolism:
  • MeNAM (1-methylnicotinamide): +364% to +551% increase ($p < 5.4 \times 10^{-13}$).
  • 2PY (N1-methyl-2-pyridone-5-carboxamide): +368% to +512% increase ($p < 2.95 \times 10^{-16}$).
• Safety & Tolerability:
  • Adverse Events: Only one mild adverse event (nausea, Grade 1) occurred in the LNAD+ group; no serious AEs.
  • Clinical Labs: No signs of hepatotoxicity (ALT/AST/GGT unchanged) or renal injury.
  • Exploratory Signals: Nominal (non-significant after correction) increases in absolute lymphocyte counts and decreases in bilirubin/albumin were observed but interpreted as hypothesis-generating.
  • Well-being: No significant changes in fatigue, anxiety, or depression scores.

5. Significance and Implications

• Therapeutic Potential: The study validates LNAD+ as a viable route for NAD+ repletion, potentially overcoming the bioavailability limitations of precursors (NR/NMN) and the instability of standard NAD+ formulations.
• Mechanistic Insight: The lack of plasma elevation coupled with high intracellular elevation and catabolite generation suggests a mechanism involving efficient cellular uptake (possibly via connexin hemichannels or rapid hydrolysis/uptake of intermediates) rather than passive diffusion.
• Aging and Immunology: The rapid increase in icNAD in healthy older adults (45–75) suggests potential for reversing age-related NAD+ depletion, which is linked to immune dysfunction (e.g., CD8+ T cell senescence). The lymphocyte trend (without inflammation) hints at improved immune cell fitness.
• Future Directions: While the 5-day window proves acute efficacy, longer-term studies are needed to assess chronic homeostasis, tissue-specific distribution (muscle, brain), and clinical outcomes in diseased populations. The study also highlights the need to monitor catabolites (MeNAM/2PY) in populations with renal impairment.

Conclusion: The RENEWAL-NAD+ trial provides robust clinical evidence that oral LathMized™ NAD+ rapidly and safely augments intracellular NAD+ pools in humans, engaging downstream metabolic flux without elevating circulating NAD, representing a significant advancement in geroscience therapeutics.